Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
ONCOLOGY RESEARCH AND TREATMENT. Bd. 47. 2024 S. 64-64
Erscheinungsjahr: 2024
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Moehler, Markus (Autor)
Janjigian, Yelena Y. (Autor)
Shitara, Kohei (Autor)
Garrido, Marcelo (Autor)
Gallardo, Carlos (Autor)
Shen, Lin (Autor)
Yamaguchi, Kensei (Autor)
Wyrwicz, Lucjan (Autor)
Skoczylas, Tomasz (Autor)
Bragagnoli, Arinilda (Autor)
Liu, Tianshu (Autor)
Tehfe, Mustapha (Autor)
Elimova, Elena (Autor)
Bruges, Ricardo (Autor)
Cleary, James M. (Autor)
Karamouzis, Michalis (Autor)
Soleymani, Samira (Autor)
Lei, Ming (Autor)
Chanaga, Carlos Amaya (Autor)
Ajani, Jaffer A. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
